Preferred Label : Narsoplimab;
NCIt synonyms : WHO 11174; Anti-MASP-2 Monoclonal Antibody OMS721;
NCIt definition : A monoclonal antibody against mannan-binding lectin (MBL)-associated serine protease-2
(MASP-2), with potential anti-thrombotic and immunomodulating activities. Upon subcutaneous
administration, narsoplimab binds to and inhibits MASP-2. This prevents the activation
of MASP-2, the cleavage of certain complement components, and the activation of the
complement lectin pathway. This inhibits complement deposition and complement-induced
thrombus formation. MASP-2, a pro-inflammatory protein, plays a key role in the activation
of the lectin complement pathway, which is a key component in the immune system, and
is associated with complement-mediated diseases, such as thrombotic microangiopathies
(TMAs), which includes hematopoietic stem cell transplant (HSCT)-related TMA, atypical
hemolytic uremic syndrome (aHUS), and thrombotic thrombocytopenic purpura (TTP).;
UNII : FT24ZQQ5RP;
CAS number : 2108782-45-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2108782-45-0
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : OMS721;
Origin ID : C119952;
UMLS CUI : C5418161;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
